Life sciences partner Katherine Wang (Shanghai) was quoted in a Jan. 22 article in International Devices & Diagnostics Monitor addressing China FDA guidelines for accepting clinical trial data for medical device trials conducted overseas.
Ms. Wang explains that CFDA guidelines are aimed at accelerating and simplifying the medical device approval process. She notes that foreign devicemakers seeking to bypass local trials should involve sufficient numbers of Chinese patients when organizing their clinical studies.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.